Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001714899-22-000101
Filing Date
2022-06-28
Accepted
2022-06-28 15:07:44
Documents
1
Period of Report
2022-03-23

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wf-form4a_165644324155351.html 4/A  
1 FORM 4/A wf-form4a_165644324155351.xml 4/A 8498
  Complete submission text file 0001714899-22-000101.txt   9873
Mailing Address 1 DNA WAY SOUTH SAN FRANCISCO CA 94080
Business Address
Tessier-Lavigne Marc (Reporting) CIK: 0001437435 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-38311 | Film No.: 221049340

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)